Target Market Segments
Point of Care Testing
The point of care testing market was valued at $13.8 billion in 2011. It is the fastest-growing segment of the $40+ billion diagnostics market, and is projected to reach $16.5 billion by 2016.
LeukoDx management is experienced in tackling the challenges that most influence success in this market - regulatory guidelines, reimbursement issues, protecting intellectual property and technology infrastructure needs. Preparation has been made to address these factors and LeukoDx is confident that we will be competitive in the market.
Flow cytometry had a market value of around $2.6 billion in 2010, and by 2015 will have an estimated value of $4.3 billion. The flow cytometry reagent market is almost the same size as the instrument market. The technology is widely applicable in such fields as molecular, marine and plant biology, protein engineering, pathology and immunology.
In today's flow cytometer market, short-term growth will be driven by smaller, more robust devices with multiple applications to meet research and clinical sector needs. In the long term, next-generation integrated point of care miniature systems will drive growth. These machines do not exist today: LeukoDx's platform technology addresses both of these growth targets and can be brought to market within three years.
Currently, flow cytometers are large, expensive, complicated, require a highly trained lab technician to operate and can take over a week to present test resuts. This prevents rapid response in patient care and severely limits access to the technology. The LeukoDx technology will revolutionize the market by offering a device that has all the technology in a smaller, less expensive and easier to use device that will give results in 10 minutes.